{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:43:59Z","timestamp":1790844239168,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01 HD095547"],"award-info":[{"award-number":["R01 HD095547"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40262-025-01495-3","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T10:07:34Z","timestamp":1745489254000},"page":"769-777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Variability in Meropenem Distribution and Clearance in Children with Sepsis: Population-Based Pharmacokinetics with Assessment of Renal Biomarkers"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6692-0884","authenticated-orcid":false,"given":"Jennifer","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah D.","family":"Momper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund V.","family":"Capparelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Avedissian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Sitapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3835-5064","authenticated-orcid":false,"given":"John S.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"4","key":"1495_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ijantimicag.2014.12.020","volume":"45","author":"AA Udy","year":"2015","unstructured":"Udy AA, De Waele JJ, Lipman J. Augmented renal clearance and therapeutic monitoring of \u03b2-lactams. Int J Antimicrob Agents. 2015;45(4):331\u20133. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.12.020.","journal-title":"Int J Antimicrob Agents"},{"key":"1495_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020445","author":"F Hefny","year":"2022","unstructured":"Hefny F, Stuart A, Kung JY, Mahmoud SH. Prevalence and risk factors of augmented renal clearance: a systematic review and meta-analysis. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14020445.","journal-title":"Pharmaceutics"},{"issue":"3","key":"1495_CR3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/phar.2231","volume":"39","author":"AM Cook","year":"2019","unstructured":"Cook AM, Hatton-Kolpek J. Augmented renal clearance. Pharmacotherapy. 2019;39(3):346\u201354. https:\/\/doi.org\/10.1002\/phar.2231.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"1495_CR4","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00467-019-04205-x","volume":"34","author":"T Van Der Heggen","year":"2019","unstructured":"Van Der Heggen T, Dhont E, Peperstraete H, et al. Augmented renal clearance: a common condition in critically ill children. Pediatr Nephrol. Jun2019;34(6):1099\u2013106. https:\/\/doi.org\/10.1007\/s00467-019-04205-x.","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"1495_CR5","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1097\/pcc.0000000000001228","volume":"18","author":"SN Avedissian","year":"2017","unstructured":"Avedissian SN, Bradley E, Zhang D, et al. Augmented renal clearance using population-based pharmacokinetic modeling in critically ill pediatric patients. Pediatr Crit Care Med. 2017;18(9):e388\u201394. https:\/\/doi.org\/10.1097\/pcc.0000000000001228.","journal-title":"Pediatr Crit Care Med"},{"issue":"1","key":"1495_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00467-018-4120-2","volume":"35","author":"E Dhont","year":"2020","unstructured":"Dhont E, Van Der Heggen T, De Jaeger A, Vande Walle J, De Paepe P, De Cock PA. Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients? Pediatr Nephrol. 2020;35(1):25\u201339. https:\/\/doi.org\/10.1007\/s00467-018-4120-2.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"1495_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.5863\/1551-6776-25.5.413","volume":"25","author":"SN Avedissian","year":"2020","unstructured":"Avedissian SN, Skochko SM, Le J, et al. Use of simulation strategies to predict subtherapeutic meropenem exposure caused by augmented renal clearance in critically ill pediatric patients with sepsis. J Pediatr Pharmacol Ther. 2020;25(5):413\u201322. https:\/\/doi.org\/10.5863\/1551-6776-25.5.413.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"1495_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/jac\/dkz408","volume":"75","author":"SN Avedissian","year":"2020","unstructured":"Avedissian SN, Rhodes NJ, Kim Y, Bradley J, Valdez JL, Le J. Augmented renal clearance of aminoglycosides using population-based pharmacokinetic modelling with Bayesian estimation in the paediatric ICU. J Antimicrob Chemother. 2020;75(1):162\u20139. https:\/\/doi.org\/10.1093\/jac\/dkz408.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1495_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1611391","volume":"376","author":"A Kaddourah","year":"2017","unstructured":"Kaddourah A, Basu RK, Bagshaw SM, Goldstein SL. Epidemiology of acute kidney injury in critically ill children and young adults. N Engl J Med. 2017;376(1):11\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1611391.","journal-title":"N Engl J Med"},{"issue":"1","key":"1495_CR10","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1097\/pcc.0000000000002541","volume":"22","author":"CL Formeck","year":"2021","unstructured":"Formeck CL, Joyce EL, Fuhrman DY, Kellum JA. Association of acute kidney injury with subsequent sepsis in critically ill children. Pediatr Crit Care Med. 2021;22(1):e58\u201366. https:\/\/doi.org\/10.1097\/pcc.0000000000002541.","journal-title":"Pediatr Crit Care Med"},{"issue":"7","key":"1495_CR11","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/pcc.0000000000002679","volume":"22","author":"R Alobaidi","year":"2021","unstructured":"Alobaidi R, Anton N, Burkholder S, et al. Association between acute kidney injury duration and outcomes in critically ill children. Pediatr Crit Care Med. 2021;22(7):642\u201350. https:\/\/doi.org\/10.1097\/pcc.0000000000002679.","journal-title":"Pediatr Crit Care Med"},{"issue":"19","key":"1495_CR12","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin c-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737\u201349. https:\/\/doi.org\/10.1056\/NEJMoa2102953.","journal-title":"N Engl J Med"},{"issue":"11","key":"1495_CR13","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.2215\/cjn.01640309","volume":"4","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4(11):1832\u201343. https:\/\/doi.org\/10.2215\/cjn.01640309.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1495_CR14","doi-asserted-by":"publisher","unstructured":"Young S, Struys E, Wood T. Quantification of creatine and guanidinoacetate using GC-MS and LC-MS\/MS for the detection of cerebral creatine deficiency syndromes. Curr Protoc Hum Genet. 2007;Chapter 17:Unit 17 3. https:\/\/doi.org\/10.1002\/0471142905.hg1703s54.","DOI":"10.1002\/0471142905.hg1703s54"},{"issue":"4","key":"1495_CR15","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.kint.2020.10.047","volume":"99","author":"CB Pierce","year":"2021","unstructured":"Pierce CB, Mu\u00f1oz A, Ng DK, Warady BA, Furth SL, Schwartz GJ. Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease. Kidney Int. 2021;99(4):948\u201356. https:\/\/doi.org\/10.1016\/j.kint.2020.10.047.","journal-title":"Kidney Int"},{"issue":"4","key":"1495_CR16","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1097\/CCM.0b013e318169245a","volume":"36","author":"DS Wheeler","year":"2008","unstructured":"Wheeler DS, Devarajan P, Ma Q, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit Care Med. 2008;36(4):1297\u2013303. https:\/\/doi.org\/10.1097\/CCM.0b013e318169245a.","journal-title":"Crit Care Med"},{"key":"1495_CR17","unstructured":"Beal S, Boeckmann L, Bauer R, Sheiner L. NONMEM user\u2019s guides. (1989\u20132009). 2009."},{"issue":"9","key":"1495_CR18","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/INF.0b013e318170f8d2","volume":"27","author":"JS Bradley","year":"2008","unstructured":"Bradley JS, Sauberan JB, Ambrose PG, Bhavnani SM, Rasmussen MR, Capparelli EV. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr Infect Dis J. 2008;27(9):794\u20139. https:\/\/doi.org\/10.1097\/INF.0b013e318170f8d2.","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"1495_CR19","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/psp4.12422","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ. NONMEM tutorial part II: estimation methods and advanced examples. CPT Pharmacomet Syst Pharmacol. 2019;8(8):538\u201356. https:\/\/doi.org\/10.1002\/psp4.12422.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"Suppl 10","key":"1495_CR20","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1002\/jcph.1128","volume":"58","author":"J Le","year":"2018","unstructured":"Le J, Bradley JS. Optimizing antibiotic drug therapy in pediatrics: current state and future needs. J Clin Pharmacol. 2018;58(Suppl 10):S108-s122. https:\/\/doi.org\/10.1002\/jcph.1128.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"1495_CR21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00431-006-0189-x","volume":"165","author":"BJ Anderson","year":"2006","unstructured":"Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165(12):819\u201329. https:\/\/doi.org\/10.1007\/s00431-006-0189-x.","journal-title":"Eur J Pediatr"},{"issue":"12","key":"1495_CR22","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1345\/aph.1E260","volume":"38","author":"EI Ette","year":"2004","unstructured":"Ette EI, Williams PJ, Lane JR. Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic studies. Ann Pharmacother. 2004;38(12):2136\u201344. https:\/\/doi.org\/10.1345\/aph.1E260.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"1495_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.5863\/1551-6776-22.4.276","volume":"22","author":"JJ Cies","year":"2017","unstructured":"Cies JJ, Moore WS 2nd, Enache A, Chopra A. Population pharmacokinetics and pharmacodynamic target attainment of meropenem in critically ill young children. J Pediatr Pharmacol Ther Jul-Aug. 2017;22(4):276\u201385. https:\/\/doi.org\/10.5863\/1551-6776-22.4.276.","journal-title":"J Pediatr Pharmacol Ther. Jul-Aug"},{"issue":"3","key":"1495_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ijantimicag.2019.06.016","volume":"54","author":"L Ehmann","year":"2019","unstructured":"Ehmann L, Zoller M, Minichmayr IK, et al. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic\/pharmacodynamic analysis. Int J Antimicrob Agents. 2019;54(3):309\u201317. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.06.016.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"1495_CR25","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.xphs.2022.01.015","volume":"111","author":"J Lan","year":"2022","unstructured":"Lan J, Wu Z, Wang X, et al. Population pharmacokinetics analysis and dosing simulations of meropenem in critically ill patients with pulmonary infection. J Pharm Sci. 2022;111(6):1833\u201342. https:\/\/doi.org\/10.1016\/j.xphs.2022.01.015.","journal-title":"J Pharm Sci"},{"issue":"1","key":"1495_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40121-021-00551-2","volume":"11","author":"Y-C Zhao","year":"2022","unstructured":"Zhao Y-C, Zou Y, Xiao Y-W, et al. Does prolonged infusion time really improve the efficacy of meropenem therapy? A prospective study in critically ill patients. Infect Dis Ther. 2022;11(1):201\u201316. https:\/\/doi.org\/10.1007\/s40121-021-00551-2.","journal-title":"Infect Dis Ther"},{"key":"1495_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01909-20","author":"J Saito","year":"2021","unstructured":"Saito J, Shoji K, Oho Y, et al. Population pharmacokinetics and pharmacodynamics of meropenem in critically ill pediatric patients. Antimicrob Agents Chemother. 2021. https:\/\/doi.org\/10.1128\/AAC.01909-20.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"1495_CR28","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1093\/jac\/dkae274","volume":"79","author":"R Morales Junior","year":"2024","unstructured":"Morales Junior R, Mizuno T, Paice KM, et al. Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation. J Antimicrob Chemother. 2024;79(10):2668\u201377. https:\/\/doi.org\/10.1093\/jac\/dkae274.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1495_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/adc.82.6.499","volume":"82","author":"ES Kilpatrick","year":"2000","unstructured":"Kilpatrick ES, Keevil BG, Addison GM. Does adjustment of GFR to extracellular fluid volume improve the clinical utility of cystatin C? Arch Dis Child. 2000;82(6):499\u2013502. https:\/\/doi.org\/10.1136\/adc.82.6.499.","journal-title":"Arch Dis Child"},{"issue":"11","key":"1495_CR30","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1007\/s00431-021-04076-1","volume":"180","author":"P Vijay","year":"2021","unstructured":"Vijay P, Lal BB, Sood V, Khanna R, Alam S. Cystatin C: best biomarker for acute kidney injury and estimation of glomerular filtration rate in childhood cirrhosis. Eur J Pediatr. 2021;180(11):3287\u201395. https:\/\/doi.org\/10.1007\/s00431-021-04076-1.","journal-title":"Eur J Pediatr"},{"issue":"8","key":"1495_CR31","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1128\/AAC.39.8.1721","volume":"39","author":"JL Blumer","year":"1995","unstructured":"Blumer JL, Reed MD, Kearns GL, et al. Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children. Antimicrob Agents Chemother. 1995;39(8):1721\u20135. https:\/\/doi.org\/10.1128\/AAC.39.8.1721.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1495_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6\u201314. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.02007.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1495_CR33","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212608","volume":"8","author":"A Ruggiero","year":"2019","unstructured":"Ruggiero A, Ariano A, Triarico S, Capozza MA, Ferrara P, Attina G. Neonatal pharmacology and clinical implications. Drugs Context. 2019;8: 212608. https:\/\/doi.org\/10.7573\/dic.212608.","journal-title":"Drugs Context."},{"issue":"1","key":"1495_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13054-017-1829-4","volume":"21","author":"L Ehmann","year":"2017","unstructured":"Ehmann L, Zoller M, Minichmayr IK, et al. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study. Crit Care. 2017;21(1):263. https:\/\/doi.org\/10.1186\/s13054-017-1829-4.","journal-title":"Crit Care"},{"key":"1495_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/IDR.S343264","volume":"15","author":"M Gijsen","year":"2022","unstructured":"Gijsen M, Elkayal O, Annaert P, et al. Meropenem target attainment and population pharmacokinetics in critically ill septic patients with preserved or increased renal function. Infect Drug Resist. 2022;15:53\u201362. https:\/\/doi.org\/10.2147\/IDR.S343264.","journal-title":"Infect Drug Resist."},{"issue":"10","key":"1495_CR36","doi-asserted-by":"publisher","first-page":"e0089721","DOI":"10.1128\/AAC.00897-21","volume":"65","author":"CY He","year":"2021","unstructured":"He CY, Ye PP, Liu B, Song L, van den Anker J, Zhao W. Population pharmacokinetics and dosing optimization of vancomycin in infants, children, and adolescents with augmented renal clearance. Antimicrob Agents Chemother. 2021;65(10):e0089721. https:\/\/doi.org\/10.1128\/AAC.00897-21.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1495_CR37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/FTD.0000000000000270","volume":"38","author":"K Hirai","year":"2016","unstructured":"Hirai K, Ihara S, Kinae A, et al. Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance. Ther Drug Monit. 2016;38(3):393\u20137. https:\/\/doi.org\/10.1097\/FTD.0000000000000270.","journal-title":"Ther Drug Monit"},{"key":"1495_CR38","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02629-20","author":"SN Avedissian","year":"2021","unstructured":"Avedissian SN, Rohani R, Bradley J, Le J, Rhodes NJ. Optimizing aminoglycoside dosing regimens for critically ill pediatric patients with augmented renal clearance: a convergence of parametric and nonparametric population approaches. Antimicrob Agents Chemother. 2021. https:\/\/doi.org\/10.1128\/AAC.02629-20.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1495_CR39","doi-asserted-by":"publisher","first-page":"10173","DOI":"10.1038\/s41598-024-60909-7","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang Y, Li H, Wang D, et al. Changes of PK\/PD of Meropenem in patients with abdominal septic shock and exploration of clinical rational administration plan: a prospective exploratory study. Sci Rep. 2024;14(1):10173. https:\/\/doi.org\/10.1038\/s41598-024-60909-7.","journal-title":"Sci Rep"},{"issue":"3","key":"1495_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106289","volume":"57","author":"A Eisert","year":"2021","unstructured":"Eisert A, Lanckohr C, Frey J, et al. Comparison of two empirical prolonged infusion dosing regimens for meropenem in patients with septic shock: a two-center pilot study. Int J Antimicrob Agents. 2021;57(3): 106289. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106289.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"1495_CR41","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1128\/AAC.04166-14","volume":"59","author":"S Jaruratanasirikul","year":"2015","unstructured":"Jaruratanasirikul S, Thengyai S, Wongpoowarak W, et al. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob Agents Chemother. 2015;59(6):2995\u20133001. https:\/\/doi.org\/10.1128\/AAC.04166-14.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01495-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01495-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01495-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T10:45:44Z","timestamp":1746787544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01495-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1495"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01495-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"2 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was supported by Grant Number R01 HD095547 to J.S.B. from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no competing interests relevant to this article to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data that support the findings of this study are not openly available for reasons of sensitivity and risk of reidentification due to its clinical nature. Data, however, are available from the authors upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The protocol for this study was approved by the University of California San Diego Institutional Review Board for Rady Children\u2019s Hospital (Project #181319, July 23, 2018).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent to participate in the study was obtained from all participants or their legal guardians.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants provided informed consent for the publication of their data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"John Bradley and Jennifer Le contributed to designing and performing the study. Data collection and analysis was performed by John Bradley, Jennifer Le, Julie Huynh, Brandon Vo, Annie Mai, Robert Mak, Jeremiah Momper, Edmund Caparelli, Helen Harvey, and Sean Avedissian. The draft of the manuscript was written by John Bradley, Jennifer Le, Julie Huynh, Brandon Vo, Annie Mai, Erin Bradley, Amy Sitapati, and Karandeep Singh and all authors reviewed and commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contribution"}}]}}